HC Wainwright Estimates Spyglass Pharma Q1 Earnings

Spyglass Pharma, Inc. (NASDAQ:SGP) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Spyglass Pharma in a report released on Friday, May 29th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.53) for the quarter. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.54) EPS and Q4 2027 earnings at ($0.53) EPS.

Several other analysts have also weighed in on SGP. Zacks Research raised Spyglass Pharma to a “hold” rating in a research note on Wednesday, March 4th. Citigroup began coverage on Spyglass Pharma in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 price objective on the stock. Leerink Partners downgraded Spyglass Pharma to a “market perform” rating in a research report on Tuesday, March 3rd. Jefferies Financial Group began coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $62.00 target price for the company. Finally, Wall Street Zen downgraded Spyglass Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Stock Performance

NASDAQ:SGP opened at $19.26 on Monday. The company has a 50-day simple moving average of $23.26. Spyglass Pharma has a twelve month low of $19.02 and a twelve month high of $32.44.

Spyglass Pharma (NASDAQ:SGP) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.02).

Hedge Funds Weigh In On Spyglass Pharma

Several large investors have recently bought and sold shares of SGP. First Light Asset Management LLC bought a new position in Spyglass Pharma in the first quarter valued at about $9,716,000. Affinity Asset Advisors LLC bought a new position in Spyglass Pharma in the first quarter valued at about $6,478,000. Monashee Investment Management LLC bought a new position in Spyglass Pharma in the first quarter valued at about $2,461,000. Bank of America Corp DE bought a new position in Spyglass Pharma in the first quarter valued at about $726,000. Finally, The Manufacturers Life Insurance Company bought a new position in Spyglass Pharma in the first quarter valued at about $308,000.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).